These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 14668809)

  • 1. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease.
    FitzGerald GA
    Nat Rev Drug Discov; 2003 Nov; 2(11):879-90. PubMed ID: 14668809
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cardiovascular risks of selective COX-2-inhibitors].
    Schrör K
    Dtsch Med Wochenschr; 2004 Dec; 129(49):2653-6. PubMed ID: 15578320
    [No Abstract]   [Full Text] [Related]  

  • 3. Cancer prevention: a new era beyond cyclooxygenase-2.
    Rigas B; Kashfi K
    J Pharmacol Exp Ther; 2005 Jul; 314(1):1-8. PubMed ID: 15805430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Specific cyclo-oxygenase-2 inhibitors in cardiovascular pathology].
    Monsuez JJ
    Arch Mal Coeur Vaiss; 2004 Jun; 97(6):632-40. PubMed ID: 15283037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicine. Estrogen's ties to COX-2 may explain heart disease gender gap.
    Couzin J
    Science; 2004 Nov; 306(5700):1277. PubMed ID: 15550635
    [No Abstract]   [Full Text] [Related]  

  • 6. Adverse cardiovascular effects of the coxibs.
    Dogné JM; Supuran CT; Pratico D
    J Med Chem; 2005 Apr; 48(7):2251-7. PubMed ID: 15801815
    [No Abstract]   [Full Text] [Related]  

  • 7. Nonsteroidal anti-Inflammatory drugs and cardiovascular risk.
    Howard PA; Delafontaine P
    J Am Coll Cardiol; 2004 Feb; 43(4):519-25. PubMed ID: 14975457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological interactions between herpesviruses and cyclooxygenase enzymes.
    Reynolds AE; Enquist LW
    Rev Med Virol; 2006; 16(6):393-403. PubMed ID: 17006962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintaining equilibrium by selective targeting of cyclooxygenase pathways: promising offensives against vascular injury.
    Deeb RS; Upmacis RK; Lamon BD; Gross SS; Hajjar DP
    Hypertension; 2008 Jan; 51(1):1-7. PubMed ID: 17998477
    [No Abstract]   [Full Text] [Related]  

  • 10. New insights into COX-2 biology and inhibition.
    Patrignani P; Tacconelli S; Sciulli MG; Capone ML
    Brain Res Brain Res Rev; 2005 Apr; 48(2):352-9. PubMed ID: 15850674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction.
    Jugdutt BI
    Circulation; 2007 Jan; 115(3):288-91. PubMed ID: 17242292
    [No Abstract]   [Full Text] [Related]  

  • 12. Involvement of cyclooxygenase-2 and EP3 prostaglandin receptor in acute herpetic but not postherpetic pain in mice.
    Takasaki I; Nojima H; Shiraki K; Sugimoto Y; Ichikawa A; Ushikubi F; Narumiya S; Kuraishi Y
    Neuropharmacology; 2005 Sep; 49(3):283-92. PubMed ID: 15925391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COX-2 inhibition as a tool to treat and prevent colorectal cancer.
    Tuynman JB; Peppelenbosch MP; Richel DJ
    Crit Rev Oncol Hematol; 2004 Nov; 52(2):81-101. PubMed ID: 15501074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for use of cyclooxygenase-2 inhibitors in prevention and treatment of bladder cancer.
    Pruthi RS; Derksen E; Gaston K; Wallen EM
    Urology; 2004 Oct; 64(4):637-42. PubMed ID: 15491687
    [No Abstract]   [Full Text] [Related]  

  • 15. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.
    Egan KM; Wang M; Fries S; Lucitt MB; Zukas AM; Puré E; Lawson JA; FitzGerald GA
    Circulation; 2005 Jan; 111(3):334-42. PubMed ID: 15655126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter.
    Davies NM; Jamali F
    J Pharm Pharm Sci; 2004 Oct; 7(3):332-6. PubMed ID: 15576013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.
    Beswick P; Bingham S; Bountra C; Brown T; Browning K; Campbell I; Chessell I; Clayton N; Collins S; Corfield J; Guntrip S; Haslam C; Lambeth P; Lucas F; Mathews N; Murkit G; Naylor A; Pegg N; Pickup E; Player H; Price H; Stevens A; Stratton S; Wiseman J
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5445-8. PubMed ID: 15454242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study.
    Bogaty P; Brophy JM; Noel M; Boyer L; Simard S; Bertrand F; Dagenais GR
    Circulation; 2004 Aug; 110(8):934-9. PubMed ID: 15302800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Getting to the heart of COX-2 inhibition.
    Breyer MD
    Cell Metab; 2005 Sep; 2(3):149-50. PubMed ID: 16154096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenase and nitric oxide systems in the gut as therapeutic targets for safer anti-inflammatory drugs.
    Whittle BJ
    Curr Opin Pharmacol; 2004 Dec; 4(6):538-45. PubMed ID: 15525540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.